Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics Inc (NASDAQ: JSPR) is a clinical-stage biotechnology company pioneering safer conditioning agents for stem cell transplants and gene therapies. This dedicated news hub provides investors and medical professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships central to advancing curative treatments.
Discover comprehensive coverage of JSPR's progress in hematopoietic stem cell research, including trial results for jsp191 and related therapeutic platforms. Our curated collection features press releases on FDA interactions, collaboration announcements with research institutions, and analyses of scientific breakthroughs in antibody-based conditioning.
Key updates include progress reports on:
• Phase clinical trials evaluating novel conditioning regimens
• Strategic licensing agreements enhancing therapeutic pipelines
• Peer-reviewed research publications validating scientific approaches
• Financial disclosures supporting continued R&D efforts
Bookmark this page for direct access to Jasper Therapeutics' official communications and third-party analyses, carefully vetted for accuracy and relevance. Check regularly for developments that could influence the future of stem cell transplantation protocols and gene therapy accessibility.
Jasper Therapeutics (NASDAQ: JSPR), a clinical-stage biotech company developing briquilimab, will present at two major healthcare investor conferences. The company will participate in the RBC Capital Markets 2025 Global Healthcare Conference on May 21, 2025, at 11:00 a.m. EDT in a fireside chat format, and the Jefferies 2025 Global Healthcare Conference on June 5, 2025, at 11:40 a.m. EDT as a presentation.
Briquilimab is a novel antibody therapy targeting KIT for mast cell-driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. Live webcasts will be available on Jasper's Investor Relations website, with replays accessible for 30 days after each presentation.
The BEACON Phase 1b/2a study in chronic spontaneous urticaria (CSU) continues enrollment, with additional data expected in Q3 2025. The SPOTLIGHT Phase 1b/2a study completed enrollment for its final cohort in chronic inducible urticaria, with data expected at EAACI Congress in June 2025. The ETESIAN study in allergic asthma continues enrollment with initial data expected in H2 2025.
Financial highlights for Q1 2025:
- Cash position: $48.8 million
- R&D expenses: $16.2 million
- G&A expenses: $5.6 million
- Net loss: $21.2 million ($1.41 per share)
Jasper Therapeutics (Nasdaq: JSPR) presented updated clinical data from its Phase 1b/2a BEACON study and four preclinical studies for briquilimab at the AAAAI 2025 Annual Meeting. The latest data, with a cut-off date of January 31, 2025, includes one month of additional dosing and follow-up from 49 participants.
The study shows that briquilimab continues to demonstrate favorable safety profile in treating chronic spontaneous urticaria (CSU), with no additional adverse events related to c-Kit blockade. The treatment resulted in rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe CSU.
Based on these positive results, Jasper plans to advance briquilimab into a Phase 2b operationally adaptive study in the second half of 2025. The company expects to report additional clinical data from approximately 70 patients treated with briquilimab doses of 180mg or higher by mid-year 2025, which will inform the final dose selection for the Phase 2b study.
Jasper Therapeutics (Nasdaq: JSPR) has announced a late-breaking oral presentation of briquilimab data from their Phase 1b/2a BEACON study in chronic spontaneous urticaria (CSU) at the upcoming 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando.
The presentation, scheduled for March 8, 2025, at 1 p.m. PST, will showcase data previously disclosed on January 8th, 2025, demonstrating briquilimab's impact on CSU patients. The abstract titled 'Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study' will be featured in the Late Breaking Research: Session 2.
Briquilimab is a novel antibody therapy targeting c-Kit, developed to address mast cell driven diseases including CSU, chronic inducible urticaria (CIndU), and asthma.
Jasper Therapeutics (JSPR) reported its Q4 and full-year 2024 financial results, highlighting significant progress in clinical trials for briquilimab, their novel antibody therapy. The company reported positive data from two key studies: the BEACON study in chronic spontaneous urticaria (CSU) and the SPOTLIGHT study in chronic inducible urticaria (CIndU).
Key clinical achievements include rapid and deep response profiles in urticaria patients, with weekly score improvements exceeding 25 points in doses ≥120mg. In the SPOTLIGHT study, 93% of participants achieved clinical response, with 83% experiencing complete response in the 120mg dose cohort.
Financial results show $71.6 million in cash and equivalents as of December 31, 2024. The company reported Q4 R&D expenses of $19.8 million, G&A expenses of $5.5 million, and a net loss of $24.3 million ($1.62 per share). Full-year 2024 resulted in a net loss of $71.3 million ($4.89 per share).
Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announced its participation in three major investor conferences this March. The company, which focuses on developing novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, will present at:
- TD Cowen 45th Annual Healthcare Conference (March 3-5, 2025) with presentation on March 3 at 1:20 p.m. EST
- Barclays 27th Annual Global Healthcare Conference (March 11-13, 2025)
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 at 12:30 p.m. EST
Live webcasts will be available on Jasper's Investor Relations website with 30-day replay access.
Jasper Therapeutics (Nasdaq: JSPR) has announced multiple presentations of data for its novel antibody therapy briquilimab at the upcoming AAAAI 2025 Annual Meeting in San Diego. The presentations include five posters and one oral session, scheduled for February 28 - March 3, 2025.
The presentations will feature additional follow-up data from the Phase 1b/2a BEACON trial evaluating briquilimab in chronic spontaneous urticaria (CSU), expanding on preliminary data disclosed on January 8th, 2025. The research focuses on briquilimab's targeting of c-Kit (CD117) for treating mast cell driven diseases including CSU, chronic inducible urticaria (CIndU), and asthma.
The presentations will cover various aspects of briquilimab's mechanism of action, including its ability to deplete mast cells across multiple tissues, inhibit stem cell factor signaling, and its effectiveness in dermatitis mouse models.
Jasper Therapeutics (Nasdaq: JSPR) has announced its participation in the upcoming Oppenheimer Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company will present in a fireside chat format on Tuesday, February 11, 2025, at 3:20 p.m. EST.
Jasper is a clinical stage biotechnology company developing briquilimab, a novel antibody therapy targeting c-Kit (CD117). The therapy aims to address mast cell driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
The presentation will be available via live webcast on Jasper's Investor Relations website under the News & Events – Events page. An archived version will remain accessible for 30 days following the live broadcast.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
